

S 1681

A bill to require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services.

Congress: 115 (2017–2019, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Jul 31, 2017

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Jul 31, 2017)

Official Text: <https://www.congress.gov/bill/115th-congress/senate-bill/1681>

Sponsor

Name: Sen. Sanders, Bernard [I-VT]

Party: Independent • **State:** VT • **Chamber:** Senate

Cosponsors

No cosponsors are listed for this bill.

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Jul 31, 2017

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
115 HR 3536	Identical bill	Aug 4, 2017: Referred to the Subcommittee on Health.

Summary (as of Jul 31, 2017)

This bill prohibits federal agencies and nonprofit entities that conduct federally funded health care research from providing a patent for a drug based on such research until the entity receiving the patent enters into a reasonable pricing agreement with the Department of Health and Human Services.

Actions Timeline

- Jul 31, 2017: Introduced in Senate
- Jul 31, 2017: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.